Novo Nordisk joins the Call to Action for gender equality

Novo NordiskYesterday, the Danish Minister for Development Cooperation Ms Ulla Tørnæs handed over a torch to Executive Vice President Lise Kingo, Novo Nordisk, at a ceremony in Copenhagen. With the torch Ms Tørnæs makes a Call to Action to leaders from around the world to help accelerate progress on the Millennium Development Goal 3 (MDG3): To empower women and promote gender equality.

"The private sector plays a critical role if we are to improve women's situation. They have the availability to promote women’s opportunities within their field of work. I am therefore glad that Novo Nordisk now has joined our global Call to Action to accelerate progress on gender equality. The company has committed to drive actions that can improve the situation for women living with diabetes in the developing world. This is the kind of action we need from all actors," says Ulla Tørnæs, Danish minister for Development Cooperation.

As torch bearer Novo Nordisk is committed to creating awareness of how diabetes will impede development and women empowerment. This will be supported by actions to effectively overcome this barrier by improved prevention, diagnosis and treatment. Addressing the adverse relationship between the global diabetes epidemic and a healthy, sustainable development is Novo Nordisk's contribution to the achievement of MDG3.

"Women are uniquely affected by diabetes that all over the world results in life-threatening complications. Women have a higher diabetes-related morbidity and mortality due to biological, cultural and socioeconomic factors. If acquired during pregnancy, diabetes causes serious problems for both the mother and the child. Moreover, women are often at a disadvantage getting diagnosed and receiving proper treatment. We simply need to change diabetes for women," says Lise Kingo.

Lise Kingo is a member of the MDG3 Champion Network established by Ms Ulla Tørnæs among other things to bring global attention to MDG3. The network has participation by internationally prominent politicians, public and private sector leaders as well as civil society representatives.

On 24 September, Novo Nordisk co-hosts a Leadership Forum on Women, Diabetes and Development in New York, organised together with the Danish minister for Development Cooperation, The Global Alliance for Women's Health and the World Diabetes Foundation.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...